When the uptake of glutamine by tumor cells is inhibited by the utility of V‐9302, CD8+ T cells gain increased access to glutamine to support their effector functions, thereby contributing to the reversal of resistance to anti‐PD‐L1 antibody therapy [215, 256]. This evidence concerns the gene CD8A and neoplasm.